Oct 2026· Bleeding Thrombosis and Vascular Biology· 0 citations
TL;DR
Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters, and this findings reinforce the highly specific lipid-lowering mechanism of inclisiran and underscore inter-individual variability in treatment response, particularly in the context of concomitant lipid-lowering therapies.
Abstract
Background and Aims. Inclisiran is a subcutaneously administrated synthetic small interfering RNA directed against proprotein convertase subtilisin–kexin type 9, leading to sustained low-density lipoprotein cholesterol (LDL-C) reduction with a twice-yearly dosing regimen. While its lipid-lowering efficacy is well established, its broader metabolic effects remain incompletely characterized. Metabolomics refers to the comprehensive analysis of small-molecule metabolites reflecting systemic biochemical activity, whereas lipoproteomics focuses on the detailed characterization of lipoprotein particles and their subclasses, providing deeper insight into lipid transport and cardiovascular risk. This study aimed to comprehensively evaluate serum metabolomic and lipoproteomic changes in patients with dyslipidemia before and after inclisiran treatment using an integrated nuclear magnetic resonance (NMR)-based approach.Methods. This observational single-center study included 69 patients with dyslipidemia treated with inclisiran in routine clinical practice. Fasting serum samples were collected at baseline and three months after treatment initiation. A total of 30 metabolites and 112 lipoprotein-related parameters were quantified using NMR spectroscopy. Paired comparisons between time points were performed using the Wilcoxon signed-rank test with false discovery rate correction. Clustering based on lipoprotein changes was conducted using the KODAMA algorithm to identify distinct response patterns.Results. Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters. Seventy-four lipoprotein variables showed significant changes. Reductions were observed across LDL, IDL, and VLDL subclasses, while some HDL-related parameters were increased. In contrast, the global metabolomic profile remained largely unchanged; trimethylamine-N-oxide (TMAO) was the only metabolite significantly increased at follow-up. KODAMA clustering identified three patient groups with heterogeneous responses. Two groups demonstrated marked lipoprotein reductions, particularly those with higher baseline LDL-related parameters, whereas one group exhibited minimal changes. Baseline TMAO levels were lower in the group with the most pronounced lipid response and increased at follow-up, potentially reflecting changes in concomitant lipid-lowering therapy rather than a direct effect of inclisiran.Conclusions. Inclisiran induces a broad and consistent improvement in lipoprotein profiles, extending beyond LDL-C reduction, while exerting only minimal effects on the global metabolomic landscape. These findings reinforce the highly specific lipid-lowering mechanism of inclisiran and underscore inter-individual variability in treatment response, particularly in the context of concomitant lipid-lowering therapies.
Profound TG reduction achieved by APOC3 siRNA therapy is associated with an apolipoprotein pattern resembling APOC3 heterozygous deficiency, as well as a coordinated anti-inflammatory response, suggesting that deep APOC3 silencing remodels lipoprotein composition and may contribute to inflammation resolution by modulat...
S. Nilsson, S. Ueckert, A. Gabrielsen et al.· European Heart Journal· 0 citations
In healthy volunteers and subjects with mild dyslipidemia, single subcutaneous doses of EDP167 demonstrated a favorable safety and tolerability profile and a dose-dependent reduction in ANGPTL3 and substantial reductions in TG, LDL-C, non-HDL-C, ApoB and remnant-C were observed.
J. Wang, B. Jiang, Shi-Long Zhong et al.· European Heart Journal· 0 citations
Targeted metabolomics confirmed seladelpar′s impact on carnitine and acylcarnitines, which facilitate fatty acid β‐oxidation, and highlighted potential pathways for future exploration in the treatment of PBC and its symptoms.
Yun-Jung Choi, Andrew J. Schwab, James Lim et al.· PPAR Research· 0 citations
GLP-1 receptor agonists confer pleiotropic vascular protection via mechanisms other than glycemic and body weight control. Comprehensive proteomic evaluations of its immunothrombosis modulatory and vascular effects remained limited.
To investigate the immunothrombosis modulatory effects of GLP-1 receptor a...
Y. Chan, S. Rakesh, T. Chan et al.· European Heart Journal· 0 citations
Mailuoning oral liquid (MLN), a standardized five-herb formula, is used for ischemic vascular diseases and shows potential in ameliorating dyslipidemia. Our previous study showed MLN alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via peroxisome proliferator-activated receptor α (PPARα)...
Si-Jia Wu, Wang-Ya Jia, Xun Zhou et al.· Frontiers in Pharmacology· 0 citations
ATO-curcuminoid co-treatment suppressed ApoB secretion but was accompanied by increased intracellular lipid accumulation, altered glucose uptake and GLUT2 expression, and apoptosis, indicating a discordant hepatic response.
A. Bakillah, Haidar A. Alsahoud, Abeer Al Otaibi et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.